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Background: One hypothesis for thyroid cancer development is its derivation from thy-
roid cancer stem cells (CSCs). Such cells could arise via different paths including from
mutated resident stem cells within the thyroid gland or via epithelial to mesenchymal tran-
sition (EMT) from malignant cells since EMT is known to confer stem-like characteristics.
Furthermore, EMT is a critical process for epithelial tumor progression, local invasion, and
metastasis formation. In addition, stemness provides cells with therapeutic resistance and
is the likely cause of tumor recurrence. However, the relevance of EMT and stemness in
thyroid cancer progression has not been extensively studied.
Methods: To examine the status of stemness in thyroid papillary cancer, we employed a
murine model of thyroid papillary carcinoma and examined the expression of stemness
and EMT using qPCR and histochemistry in mice with a thyroid-specific knock-in of onco-
genic Braf (LSL-Braf(V600E)/TPO-Cre). This construct is only activated at the time of thyroid
peroxidase (TPO) expression in differentiating thyroid cells and cannot be activated by
undifferentiated stem cells, which do not express TPO.
Results:There was decreased expression of thyroid-specific genes such asTg and NIS and
increased expression of stemness markers, such as Oct4, Rex1, CD15, and Sox2 in the
thyroid carcinoma tissue from 6-week-old BRAFV600E mice indicating the dedifferentiated
status of the cells and the fact that stemness was derived in this model from differentiated
thyroid cells. The decreased expression of the epithelial marker E-cadherin and increased
EMT regulators including Snail, Slug, andTGF-β1 andTGF-β3, and the mesenchymal marker
vimentin demonstrated the simultaneous progression of EMT and the CSC-like phenotype.
Stemness was also found in a cancer thyroid cell line (named Marca cells) derived from
one of the murine tumors. In this cell line, we also found that overexpression of Snail
caused up-regulation of vimentin expression and up-regulation of stemness markers Oct4,
Rex1, and CD15, with enhanced migration ability of the cells. We also showed thatTGF-β1
was able to induce Snail and vimentin expression in the Marca cell thyroid cancer line,
indicating the induction of EMT in these cells, and this induction of EMT and stemness
was significantly inhibited by celastro a natural inhibitor of neoplastic cells.
Conclusion: Our findings support our earlier hypothesis that stemness in thyroid cancer is
derived via EMT rather than from resident thyroid stem cells. In mice with a thyroid-specific
knock-in of oncogenic Braf (LSL-Braf(V600E)/TPO-Cre), the neoplastic changes were depen-
dent on thyroid cell differentiation and the onset of stemness must have been derived from
differentiated thyroid epithelial cells. Furthermore, celastrol suppressed TGF-β1 induced
EMT in thyroid cancer cells and may have therapeutic potential.
Keywords: epithelial–mesenchymal transition, cancer stem cells, thyroid papillary carcinoma, celastrol, thyroid
peroxidase, thyroglobulin, Braf
INTRODUCTION
The role of stem cells in thyroid cancer development remains
unclear (1). There is no doubt that the thyroid gland retains a
significant number of resident stem cells as shown in mice and
human thyroid tissue (2–5) but the role of thyroid cancer stem
cells (CSCs) in tumor formation and progression is less certain (1,
6). There are two major possibilities. The first is that neoplastic
transformation of a normal resident thyroid stem cell takes place
and leads to tumor formation during which the stem cells undergo
asymmetric divisions to secure their own survival as we have previ-
ously demonstrated (7). The second possibility is that stemness in
thyroid cancer is derived directly from malignant thyroid epithe-
lial cells via epithelial to mesenchymal transition (EMT). This is
a well-known biologic process defined by the loss of epithelial-
specific characteristics, the acquisition of a fibroblast-like mor-
phology, reduced cellular adhesion, and increased motility during
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embryonic development (8). Cells undergoing EMT develop stem
cell-like features such as the ability to self-renew (9). From a mol-
ecular point of view, EMT is characterized by the loss of epithelial
markers, including E-cadherin and cytokeratins and the gain of
mesenchymal-like gene expression program, such as fibronectin,
vimentin, and N-cadherin (8). The use of a mouse model in
which the malignant transformation can only occur in differenti-
ated thyroid cells expressing thyroid peroxidase (TPO) is a simple
approach to answering the question of where stemness is derived
from in thyroid cancer. Our data point clearly to the important role
of EMT in providing stem-like characteristics in papillary thyroid
cancer.
Epithelial to mesenchymal transition is also a commonly
accepted key pathologic mechanism in epithelial tumor progres-
sion and has been well shown to allow acquisition of stem-like
properties by cancer cells (8, 10, 11). The connection between
the loss of E-cadherin and the gain of vimentin expression by
cancer cells has been established by many studies (12) and has
been associated with the development of invasive cancer, metasta-
tic dissemination, and poor clinical prognosis in various human
tumors (8) including thyroid carcinomas (13, 14). Several dis-
tinct mechanisms of E-cadherin down-regulation and vimentin
up-regulation have been described. In particular, transforming
growth factor-β (TGF-β) (including TGF-β1, TGF-β2, and TGF-
β3 isoforms) has been shown to regulate the expression of genes
that play key roles in a large variety of biological phenomena,
ranging from tissue remodeling to tumor initiation and progres-
sion (15). TGF-β1 induced overexpression of all stemness genes
tested including Oct4, Nanog, Sox2, and CD133 and caused loss of
epithelial morphology, assumption of a fibroblast-like appearance,
and up-regulation of vimentin, Slug, Twist and down-regulation
of cytokeratin and E-cadherin (16). Several zinc-finger transcrip-
tional factors, such as Snail (17, 18), Slug (19), or Twist (20),
serve as downstream effectors of the TGFβ pathway and have been
shown to induce the EMT through direct or indirect suppression of
E-cadherin and up-regulation of vimentin transcription in cancer
and thus contribute to tumor cell growth, migration, and invasion
(8, 21).
In this report, we studied thyroid papillary cancer in mice
with a thyroid-specific knock-in of oncogenic Braf [LSL-
Braf(V600E)/TPO-Cre] (22) in order to determine if stemness was
present in such tumors and whether EMT was the source of such
characteristics.
MATERIALS AND METHODS
MICE
BrafV600E mice with a thyroid-specific knock-in of BrafV600E
were established by crossing LSL-BrafV600E mice, in which a latent
Braf mutant knock-in allele can be activated by Cre recombinase
through excision of a floxed STOP cassette (23), with TPO-Cre
mice, which express Cre under the control of the human TPO
promoter (24), which is active only in thyroid follicular cells begin-
ning at E14.5. Mice were in mixed genetic backgrounds. Both
LSL-BrafV600E mice and TPO-Cre mice were kindly provided
by Dr. James A. Fagin (Memorial Sloan-Kettering Cancer Center).
All procedures were approved by the Institutional Animal Care
Committee of Icahn School of Medicine at Mount Sinai.
MARCA CELLS – A BRAFV600E CANCER CELL LINE
Primary tumors of BrafV600E mice were minced and resuspended
in RPMI 1640 with 10% fetal bovine serum (FBS) containing
100 U/ml type I collagenase (Sigma) and 1 U/ml dispase (Roche).
Enzymatic digestion was carried out for 45 min at 37°C. Then, cells
were seeded in RPMI 1640 supplied with 10% FBS, 100 IU peni-
cillin/ml, and 100µg/ml streptomycin. After growing to conflu-
ence, cells were passaged. The doubling time of this line was 35.75 h
and the cells retained the Braf mutation as shown by PCR genotyp-
ing of DNA isolated from WT and heterozygous LSL-BrafV600E
(without Cre) thyroids and the Marca cells (data not shown).
PLASMIDS AND TRANSDUCTION
The pCMV6-Snail vector was electroporated into thyroid can-
cer cells (Neon transfection system; Invitrogen Life Technologies),
and after 2 days, the cells were cultured in G418 (0.8 mg/mL) for
4 weeks until resistant clones were established. High-expressing
clones were chosen for expansion into stable lines.
CELL PROLIFERATION AND VIABILITY ASSAYS
Cells were plated in 96-well plates, incubated for 24 h at 37°C, and
treated with TGF-β1 (R&D), 0.5µM Celastrol (Sigma) for 48 h.
Proliferation of cells was measured using a Cell Counting Kit-8
(Dojindo) according to the manufacturer’s protocol.
DIFFERENTIATION OF THYROID CSCs INTO ADIPOCYTES
Marca and MarcaSnail cells were cultured in medium alone
or medium supplemented with 10µg/mL transferrin, 0.5 mg/
mLinsulin, 0.2 nM T3, 1µM dexamethasone, and 1 mU/mL TSH
for up to 15 days. Cells were then collected for analysis.
RNA ISOLATION AND RT-PCR
Total RNA was extracted from BRAFV600E mice thyroid tumor tis-
sues and normal thyroid gland,and cultured human thyroid cancer
cells using the RNeasy system (Qiagen Ltd). cDNA synthesis was
performed using the SuperScript III system (Invitrogen Corp.).
Quantitative (q)RT-PCR was performed by using the SYBER
Green PCR system on a StepOnePlus instrument (Applied Biosys-
tems). Relative expression levels of each RT-PCR product was
analyzed using the 2−∆∆CT method and normalized to the expres-
sion of the housekeeping gene GAPDH. Data presented (mean) are
from three independent experiments in which all sample sets were
analyzed in triplicate.
IMMUNOHISTOCHEMISTRY
Paraffin-embedded, formalin-fixed tumor tissues from BrafV600E
mice and normal thyroid gland from same strain mice were sec-
tioned into 6µm thick slices. Sections were deparaffinized in
xylene and rehydrated in a series of graded ethanol, and their anti-
gens were retrieved by heating the slides in a citrate buffer (pH 6.0).
Endogenous peroxidase activity was quenched with 0.3% H2O2 in
methanol for 10 min at room temperature. The sections were then
incubated for 20 min with 2.5% normal house blocking serum.
This procedure was followed by incubation with the primary anti-
bodies at proper dilution overnight at 4°C. Negative controls were
obtained by replacing the primary antibodies with control iso-
type IgG. Staining was visualized using the ImmPRESS™ reagent
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(Vector Laboratories, Burlingame, CA, USA) detection system
with peroxidase substrate solution. Slides were counterstained in
hematoxylin and coverslipped in synthetic media.
WOUND-HEALING ASSAY
Cells were plated in six-well culture plates in complete culture
medium and grown to 90% confluence. A wound was made by
scrapping with a sterilized 100µl pipette tip in the middle of the
cell monolayer. Cells were then cultured with fresh complete cul-
ture medium containing 5 ng/ml TGFβ with or without 0.5µM
celastrol treatment for 24 h. After that, the ability of cells to migrate
into the cleared section was observed and photographed.
RESULTS
EXPRESSION OF THYROID-SPECIFIC GENES AND STEM CELL MARKERS
qRT-PCR analysis were performed for thyroid-specific markers in
total mRNA from 6-week old BRAFV600E murine thyroid tumors
and wild type normal thyroid. Expression of Tg and NIS was
markedly decreased in the tumor tissue (Figure 1A), while the stem
cell markers (Oct4, Rex1, CD15, and Sox2), although detectable in
normal thyroid, were greatly increased in the neoplastic tissues
(Figure 1B). These data indicated the undifferentiated state of the
BRAFV600E tumor specimens and indicated the presence of cells
with CSC-like features. These results were confirmed by immuno-
histochemical analysis of Tg, which was barely detectable in the
tumor tissue while Oct4 was overexpressed (Figures 1C–F).
EXPRESSION OF EMT MARKERS IN THYROID CANCER
The hallmark of EMT is the down-regulation of E-cadherin and
the up-regulation of vimentin expression. A significant loss of
E-cadherin gene expression and an increase in vimentin gene
expression was seen in the BRAFV600E thyroid tumors compared
to normal thyroid (Figure 2A) and similar data were obtained
by immunohistochemistry where vimentin staining was highly
positive only in BRAFV600E tumor specimens (Figures 2B–E).
Morphologically, thyroid cancer cells differed from the polarized,
epithelial shape of the wild type thyroid cells, and appeared as a
spindle-shaped phenotype (Figures 2C,E). The data demonstrated
that while E-cadherin was well expressed in normal thyroid tissue,
its expression was markedly decreased and vimentin expression
up-regulated in the thyroid carcinomas from the transgenic mice
over-expressing BRAFV600E (25). Such information supported the
transition of thyroid cells into undifferentiated CSC-like cells by
passing through EMT (9, 26).
EXPRESSION OF EMT INDUCERS IN THYROID CANCER
TGF-β is a multifunctional cytokine that plays a dual role in cancer;
in early stages it inhibits tumor growth, whereas later it promotes
invasion and metastasis formation (27–29). TGF-β is also a known
major inducer of EMT and its pro-invasive action is thought to be
via EMT induction of a series of transcriptional repressors includ-
ing Snail, Slug, and Twist (28, 30) (Figure 3A). We found that
TGF-β, Snail, and Slug were highly expressed in the murine thyroid
cancer tissue (Figures 3B,C). TGF-β binds to TGF-βRII that subse-
quently phosphorylates the TGF-βRI activin-receptor like kinase
5, which in turn phosphorylates Smad2 and Smad3 (28). Then
the complex of Smad proteins translocates into the nucleus where
it is able to interact with the Snail and Slug transcription fac-
tors and jointly regulate target genes, inducing down-regulation
of the epithelial marker E-cadherin and up-regulation of the
FIGURE 1 | Expression of thyroid-specific genes and stem cell markers in
mouse thyroid and thyroid tumor. (A,B) Expression of thyroid-specific
genes (A) and stem cell markers (B) in mouse normal thyroid gland and
BRAFV600E mice thyroid tumors as measured by qRT-PCR. The data were
normalized using GAPDH as an endogenous control. The results are
expressed as mean±SEM of three independent experiments.
(C–F) Representative images of immunostaining of Tg (C,D) and OCT4
(E,F) in normal thyroid gland (C,E) and thyroid tumor tissue (D,F).
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FIGURE 2 | Expression of EMT markers in normal mouse thyroid and
thyroid tumor. (A) Expression of E-cadherin and vimentin in normal
mouse thyroid and BRAFV600E mice thyroid tumor by qRT-PCR. The data
were normalized using GAPDH as an endogenous control. The results
are expressed as mean±SEM of three independent experiments with
three parallels. (B–E) Representative images of immunostaining of
E-cadherin (B,C) and vimentin (D,E) in normal mouse thyroid (B,D) and
thyroid tumor (C,E).
FIGURE 3 | Expression of EMT inducers. (A) Schematic illustration of
EMT signaling. (B,C) Expression of TGF-β1, TGF-β2R, and TGF-β3 (B), and
SNAIL and SLUG (C) in normal mouse thyroid and thyroid tumor by
qRT-PCR. The data were normalized using GAPDH as an endogenous
control. The results are expressed as mean±SEM of three independent
experiments with three parallels. *p<0.05.
mesenchymal marker vimentin (31). We found that the expression
of TGF-β1, TGF-β2R, and TGF-β3 were all increased in BRAFV600E
mice thyroid tumors compared to wild type normal thyroid tissue
(Figure 3B).
Expression of Snail has been detected in many different types of
primary human cancers, including breast, colon, and stomach can-
cer (32). Here, we observed that expression of both Snail (sixfold)
and Slug (twofold) was increased in BRAFV600E murine thyroid
tumor tissue compared to normal thyroid (Figure 3C). The results
demonstrated an inverse relationship between E-cadherin and
TGF-β1 or Snail expression (33) consistent with TGF-β1 con-
tributing to the induction of EMT in thyroid cancer via the Snail
family of transcription factors.
ECTOPIC EXPRESSION OF SNAIL ENHANCES EMT IN THYROID CANCER
CELLS
Increased expression of Snail, Slug, Twist, ZEB1, and ZEB2 expres-
sion in thyroid cancers has been well demonstrated (34, 35).
Snail appears to play a fundamental role in EMT and its expres-
sion is associated with invasiveness, metastases, tumor recurrence,
and poor prognosis (36). Snail induction of EMT and CSC-like
properties has been described in other cancers including breast
and squamous cell carcinoma (37, 38). To study the function
of Snail in thyroid cancer cells, we developed a thyroid cancer
cell line (the Marca cell line) from the murine tumors initi-
ated by oncogenic Braf (LSL-Braf(V600E)/TPO-Cre) and trans-
fect the cells with pCMV6-SNAIL. Over-expression of Snail after
transfection was demonstrated by qRT-PCR (Figure 4A). To
test whether the expressed Snail was functional, we performed
qRT-PCR for the EMT markers. Expression of the mesenchymal
marker vimentin was markedly increased by over-expression of
Snail compared to untransfected cells, as detected by qRT-PCR,
but did not affect E-cadherin expression (Figure 4B). The stem
cell markers Oct4, Rex1, and CD15 were also increased in cells
over-expressing Snail compared to the control cells (Figure 4C).
Furthermore, after being cultured in adipocyte differentiation
medium, early adipocyte differentiation markers such as the fatty
acid-binding protein 4 (FABP4) and CCAAT-enhancer-binding
protein α (CEBP α) were markedly increased in cells over-
expressing Snail compared to the control cells (Figure 4D). The
results indicated the multipotential of cells over-expressing Snail.
The same morphological changes of elongated and spindle-like
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FIGURE 4 | Over-expression of Snail in BRAFV600E thyroid cancer cells
induced EMT. Expression of Snail (A); E-cadherin and vimentin (B); and
Oct4, Rex1, and CD15 (C) in thyroid cancer cells before and after transfection
with the pCMV6-Snail vector. (D) Shows expression of adipocyte
differentiation markers FABP4 and CEBPα in thyroid cancer cells before and
after transfection with the pCMV6-Snail vector. Cells were analyzed after
culture with adipocyte differentiation medium for 15 days. The results are
expressed as mean±SEM of three independent experiments with three
parallels. (E) Migratory ability of thyroid cancer cells before and after
transfection with the pCMV6-Snail vector.
shapes appeared to be further induced by such over-expression.
In addition, the migration of cells across an artificial wound was
increased with over-expression of Snail (Figure 4E). The results
indicated that Snail over-expression induced EMT and the CSC-
like phenotype in thyroid cancer cells and this enhanced the
potential for cancer cell migration.
CELASTROL SUPPRESS TGF-β1 INDUCED EMT
As described, there is evidence that TGF-β can induce EMT,
which participates in the early stage of metastasis formation in
a variety of epithelial tumors and this action is mediated by the
Snail signaling pathway (15, 16). Celastrol, a compound used
in traditional Chinese medicine, has been reported to suppress
cancer cell migration by inhibiting TGF-β1 induced EMT (39).
We found that celastrol (0.5µM) did not reduce the cancer cell
line viability (Figure 5A) but attenuated the effects of TGF-β1
on stem cell gene expression (Figures 5B,C). While treatment
with TGF-β1 induced prominent morphological changes in the
thyroid cancer cells, including elongated and spindle-like shapes,
they were noticeable suppressed by co-treatment with celastrol
(Figure 5D). Co-incubation with celastrol also reversed TGF-β1-
mediated induction of cell migration. The results were scored
using a double-blind method by analyzing several areas of the
wound (Figure 5E). These findings showed that celastrol was able
to inhibit the effects of TGF-β1 induced EMT in BRAFV600E cancer
cells.
DISCUSSION
In this study, using mice with a thyroid-specific knock-in of onco-
genic Braf (LSL-Braf(V600E)/TPO-Cre), the thyroid epithelial
cells became transformed and progressed to invasive carcinomas
with a very short latency as shown by neoplastic transformation
present at birth. These mice also become profoundly hypothy-
roid due to dysregulation of genes involved in thyroid hormone
biosynthesis and consequently develop high TSH levels (22). We
demonstrated the down-regulation of thyroid-specific markers
(Tg and NIS) in their cancer tissue and this was reflected in isolated
thyroid cancer cells derived from the tumors. We also found that
expression of the epithelial marker E-cadherin was diminished.
In contrast, there was up-regulation of stem cell markers (Oct4,
Rex1, CD15, and Sox2) and the mesenchymal marker vimentin
as evidenced by immunohistochemistry and RT-PCR. These data
confirmed that EMT was induced in the thyroid carcinoma model
of BrafV600E mice (25) and, in particular, also demonstrated that
thyroid cells acquire differentiated CSC-like properties by passing
through EMT rather than deriving from resident stem cells which
would not be activated by the TPO-dependent construct initiating
the neoplastic response (9, 22, 26).
Epithelial to mesenchymal transition is a normal morphologi-
cal event during embryonic development, tissue remodeling, and
wound-healing but has also been shown to occur in neoplastic
cells, especially in metastases (8). By the EMT processes, epithe-
lial cells acquire fibroblast-like properties and exhibit reduced
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FIGURE 5 | Celastrol attenuatedTGF-β1 induced EMT effects in thyroid
cancer cells from BRAFV600E mice. (A) Cell viability of the thyroid cancer cells
treated with celastrol for 48 h and cell viability was analyzed using a cell
counting Kit-8. (B,C) Expression of EMT related markers Snail, E-cadherin, and
vimentin (B) and Stem cell markers Oct4, Rex1, CD15, and Sox2 (C) in thyroid
cells treated with TGF-β1 (5 ng/ml), or TGF-β1(5 ng/ml) and Celastrol (0.5µM),
or the same concentration of vehicle (DMSO) for 72 h using qRT-PCR. The
results are expressed as mean±SEM of three independent experiments with
three parallels. **p<0.01 or *p<0.05 indicated when thyroid cancer cells
treated with TGF-β1 compared with cells treated with vehicle. (D) Morpho-
logical changes of thyroid cancer cells treated with TGF-β1 (5 ng/ml), or TGF-β1
(5 ng/ml) and Celastrol (0.5µM), or the same concentration vehicle (DMSO)
for 72 h. (E) The wound-healing results were scored in a double-blind method
analyzing several areas of the wound after cells treated as above.
intercellular adhesion and increased motility providing cells
undergoing EMT with cancer stem cell properties including
enhanced invasive abilities and chemoresistance (9, 11). Such cells
exhibit down-regulated E-cadherin and up-regulated vimentin
expression as part of the acquisition of these changes, which have
been shown to be induced by TGF-β1 (40) or increased expression
of the transcription factor Snail (30, 37, 41).
Hence, EMT can be provoked by signals that cells receive
from their microenvironment, such as TGF-β (15, 42) and sev-
eral transcription factors have been implicated in the control
of EMT in addition to Snail and including Slug, Twist, ZEB1/2,
SIP1, and E12/E47 (29, 36, 43) all of which can be induced by
TGF-β (18). In agreement, we found enhanced expression of the
Snail family of EMT inducers (including Snail and Slug) and
TGF-β1, TGF-β3, and TGF-βRII in the murine papillary thy-
roid carcinoma samples as shown in previous studies (13, 35,
44). Recent work has also demonstrated that thyroid cancer,
which developed in BRAFV600E mice were susceptible to TGF-
β1 induced EMT (25) and BRAFV600E promoted invasiveness of
thyroid cancer cells by decreasing E-cadherin expression through
a Snail-dependent mechanism (45). We also demonstrated that
TGF-β1 or over-expression of Snail dramatically increased the
mesenchymal marker vimentin and stem cell markers in thyroid
cancer cells derived from BRAFV600E mice. Furthermore, celastrol,
a plant triterpene derived from the root of “Thunder of God Vine”
(Tripterygium wilfordii Hook F.), exhibited anticancer potential
and inhibited TGF-β1 induced EMT in the neoplastic cells (39,
46). Our findings demonstrated that celastrol attenuated TGF-
β1 induced EMT and stemness related gene changes and cellular
migration. However, the mechanism of this inhibition requires
further clarification.
In conclusion, our results suggested that the thyroid papil-
lary cancer of BRAFV600E mice undergo EMT and dedifferentiate
to acquire stem cell-like features. TGF-β1 treatment and over-
expression of Snail in thyroid cancer cells derived from BRAFV600E
mice further reinforced EMT, while celastrol attenuated the TGF-
β1 effects. Our findings provide strong evidence that thyroid
cancer stemness in murine papillary cancer is derived via the EMT
process and that thyroid CSCs are not derived from mutated thy-
roid stem cells. Hence, these data support the stochastic model
where every malignant thyroid cancer cell has the potential to act
as a CSC rather than CSCs being a biologically distinct subset
within the malignant cell population.
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